Beyond ADMET: AI for medicines safety stakeholder survey

AI-generated atlas summary

Why this is in the atlas

Gov.uk says the MHRA and the Regulatory Innovation Office are inviting organizations to share views on how artificial intelligence is used in medicines development. The headline suggests a stakeholder survey focused on medicines safety and AI beyond traditional ADMET questions. This matters because it shows regulators are still shaping how AI should be assessed in health and life sciences, an important example of policy and safety oversight.

Generated from the article title and available source metadata. Verify details with the original publisher.

• safety